Paul C. Grint - 24 Jun 2022 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Director
Signature
/s/ Milton H. Werner, attorney-in-fact
Issuer symbol
IKT
Transactions as of
24 Jun 2022
Net transactions value
$0
Form type
4
Filing time
28 Jun 2022, 21:00:30 UTC
Previous filing
29 Jun 2021
Next filing
05 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (right to buy) Award $0 +40,000 $0.000000 40,000 24 Jun 2022 Common Stock 40,000 $0.8100 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This entire stock option grant will vest 100% in a single tranche on the earlier of June 24, 2023 or the day prior to the next annual meeting of stockholders.